All-trans Retinoic Acid (ATRA) Suppresses Transcription of Human Papillomavirus Type 16 (HPV16) in a Dose-dependent Manner

Zsolt Faluhelyi, Imre Rodler, Andras Csejtey, Stephen K. Tyring, Istvan A. Ember, Istvan Arany

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Earlier we found that SiHa cervical squamous carcinoma cells that harbor HPV type 16 respond to ATRA treatment in a dose-dependent manner: high-dose (10-5-10-4 M) but not low-dose (10-7-10 -6 M) ATRA induced growth arrest. Growth of HPV-infected cells is highly dependent on the expression of the viral E6/E7 proteins. Thus, targeting expression of the viral E6/E7 genes might influence growth properties of HPV-infected cells. Here, we demonstrated that high-dose ATRA inhibited expression of HPV16 E7 through suppression of the HPV16 promoter (p97) activity. Gelshift assay (EMSA) revealed that binding of the AP-1 transcription factor to an oligonucleotide originated from the HPV type 16 promoter was diminished after high-dose, but not low-dose ATRA treatment. This suggests that high-dose ATRA suppresses HPV 16 promoter activity, at least in part, via a decreased AP-1 binding. Our data might be useful in treatment of cervical dysplasias and/or carcinomas.

Original languageEnglish
Pages (from-to)807-809
Number of pages3
JournalAnticancer research
Volume24
Issue number2 B
Publication statusPublished - Mar 1 2004

Keywords

  • E7
  • HPV16
  • Retinoids
  • Transcription

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'All-trans Retinoic Acid (ATRA) Suppresses Transcription of Human Papillomavirus Type 16 (HPV16) in a Dose-dependent Manner'. Together they form a unique fingerprint.

  • Cite this